Garsorasib in patients with KRAS^G12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.

已完结 10 由 up 发布于 2025/8/28 3:08:57

DOI:10.1016/S2213-2600(24)00110-3
作者：Ziming Li,?Xiaomin Dang,?Dingzhi Huang,?Shi Jin,?Weiwei Li,?Jianhua Shi,?Xicheng Wang,?Yiping Zhang,?Zhengbo Song,?Junping Zhang,?Wu Zhuang,?Xuewen Liu,?Liyan Jiang,?Xiangjiao Meng,?Mingfang Zhao,?Jia
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRASG12C inhibitor, has shown promising antitumour activity in patients with KRASG12C-mutated (ie, Gly12Cys) non-small-

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Trochlear Dysplasia as Shown by Increased Sulcus Angle Is Associated With Osteochondral Damage in Patients With Patellar Instability

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.

Garsorasib in patients with KRAS^G12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.